RU2020142739A - Ингибиторы mdm2 и их комбинации - Google Patents
Ингибиторы mdm2 и их комбинации Download PDFInfo
- Publication number
- RU2020142739A RU2020142739A RU2020142739A RU2020142739A RU2020142739A RU 2020142739 A RU2020142739 A RU 2020142739A RU 2020142739 A RU2020142739 A RU 2020142739A RU 2020142739 A RU2020142739 A RU 2020142739A RU 2020142739 A RU2020142739 A RU 2020142739A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical combination
- cancer
- combination according
- inhibitor
- pharmaceutical
- Prior art date
Links
- 239000012819 MDM2-Inhibitor Substances 0.000 title claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 17
- 238000000034 method Methods 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 4
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 4
- 210000001072 colon Anatomy 0.000 claims 4
- 229940121647 egfr inhibitor Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010038038 rectal cancer Diseases 0.000 claims 4
- 201000001275 rectum cancer Diseases 0.000 claims 4
- 229940125431 BRAF inhibitor Drugs 0.000 claims 3
- 229940124647 MEK inhibitor Drugs 0.000 claims 3
- 239000012828 PI3K inhibitor Substances 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 2
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 229960002465 dabrafenib Drugs 0.000 claims 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 claims 1
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical group N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims 1
- IHGVAVLSTPCCJP-UHFFFAOYSA-N 4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C1C IHGVAVLSTPCCJP-UHFFFAOYSA-N 0.000 claims 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical group N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims 1
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 239000012664 BCL-2-inhibitor Substances 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 1
- 208000029862 Barrett adenocarcinoma Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 239000005461 Canertinib Substances 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 1
- 208000012609 Cowden disease Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 102100030708 GTPase KRas Human genes 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 1
- 206010069755 K-ras gene mutation Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 229940083338 MDM2 inhibitor Drugs 0.000 claims 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims 1
- 229950002826 canertinib Drugs 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical group O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229950007440 icotinib Drugs 0.000 claims 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 claims 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000006385 lung benign neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 229950008001 matuzumab Drugs 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 229950008835 neratinib Drugs 0.000 claims 1
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 claims 1
- 229950010203 nimotuzumab Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 claims 1
- 229950006299 pelitinib Drugs 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- AGBSXNCBIWWLHD-FQEVSTJZSA-N siremadlin Chemical compound COC1=NC(OC)=NC=C1C(N1C(C)C)=NC2=C1[C@H](C=1C=CC(Cl)=CC=1)N(C=1C(N(C)C=C(Cl)C=1)=O)C2=O AGBSXNCBIWWLHD-FQEVSTJZSA-N 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 229960004066 trametinib Drugs 0.000 claims 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
- 229960001183 venetoclax Drugs 0.000 claims 1
- 208000009540 villous adenoma Diseases 0.000 claims 1
- 229950008250 zalutumumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562211080P | 2015-08-28 | 2015-08-28 | |
| US62/211,080 | 2015-08-28 | ||
| US201562243337P | 2015-10-19 | 2015-10-19 | |
| US62/243,337 | 2015-10-19 | ||
| US201562250574P | 2015-11-04 | 2015-11-04 | |
| US62/250,574 | 2015-11-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018110770A Division RU2740091C2 (ru) | 2015-08-28 | 2016-08-24 | Ингибиторы mdm2 и их комбинации |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020142739A true RU2020142739A (ru) | 2021-01-15 |
| RU2020142739A3 RU2020142739A3 (enExample) | 2021-05-20 |
Family
ID=56877086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020142739A RU2020142739A (ru) | 2015-08-28 | 2016-08-24 | Ингибиторы mdm2 и их комбинации |
| RU2018110770A RU2740091C2 (ru) | 2015-08-28 | 2016-08-24 | Ингибиторы mdm2 и их комбинации |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018110770A RU2740091C2 (ru) | 2015-08-28 | 2016-08-24 | Ингибиторы mdm2 и их комбинации |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20190060309A1 (enExample) |
| EP (2) | EP4241850A3 (enExample) |
| JP (2) | JP2018528206A (enExample) |
| KR (1) | KR20180041677A (enExample) |
| CN (2) | CN108348520A (enExample) |
| AU (2) | AU2016314082B2 (enExample) |
| CA (1) | CA2992221C (enExample) |
| ES (1) | ES2962460T3 (enExample) |
| IL (2) | IL257015B (enExample) |
| RU (2) | RU2020142739A (enExample) |
| WO (1) | WO2017037579A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| WO2018075823A1 (en) | 2016-10-19 | 2018-04-26 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating cancer |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| WO2018183762A1 (en) * | 2017-03-29 | 2018-10-04 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating cancer |
| AU2018242612B2 (en) * | 2017-03-31 | 2020-05-21 | Novartis Ag | Dose and regimen for an HDM2-p53 interaction inhibitor in hematological tumors |
| WO2019040511A1 (en) * | 2017-08-22 | 2019-02-28 | University Of Maryland Batimore | DOUBLE INHIBITORS OF BCL-2 AND HDM2 FAMILIES BY CO-MIMETTISM OF ALPHA BH3 AND P53 PROPELLERS |
| CN118459413A (zh) * | 2017-09-26 | 2024-08-09 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| EP3694518A1 (en) * | 2017-10-12 | 2020-08-19 | Novartis AG | Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers |
| CN111655258B (zh) * | 2017-12-31 | 2025-03-21 | 常青树生物科学公司 | 用于冷冻保存的组合物和其使用方法 |
| WO2019174576A1 (zh) * | 2018-03-12 | 2019-09-19 | 罗欣药业(上海)有限公司 | 咪唑并吡咯酮化合物及其应用 |
| MX2020009614A (es) * | 2018-03-20 | 2020-10-07 | Novartis Ag | Combinaciones farmaceuticas. |
| AU2019314624B2 (en) * | 2018-07-31 | 2022-03-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| CA3095699A1 (en) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| MX2020009759A (es) | 2018-07-31 | 2020-10-08 | Ascentage Pharma Suzhou Co Ltd | Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop. |
| JP2022514280A (ja) * | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | Ｍｄｍ２阻害剤のための延長低用量レジメン |
| EP4003332A4 (en) * | 2019-07-26 | 2023-05-10 | Ascentage Pharma (Suzhou) Co., Ltd. | PHARMACEUTICAL COMPOSITION OF AN MDM2 INHIBITOR AND ITS USE TO PREVENT AND/OR TREAT DISEASES |
| WO2021110097A1 (en) * | 2019-12-03 | 2021-06-10 | Ascentage Pharma (Suzhou) Co., Ltd. | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| CA3178927A1 (en) * | 2020-05-26 | 2021-12-02 | Hanmi Pharm. Co., Ltd. | Belvarafenib for use in cancer treatment |
| CN115124533A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法和其医药上的用途 |
| JP2024157057A (ja) * | 2021-06-29 | 2024-11-07 | 国立大学法人 東京大学 | バレット食道の治療用組成物 |
| CN117562907B (zh) * | 2023-11-17 | 2025-08-22 | 广州医科大学 | 一种提升抗癌效果的可口服吉非替尼复合物及其制备方法与应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960614B2 (en) | 2000-07-19 | 2005-11-01 | Warner-Lambert Company | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids |
| MXPA04008893A (es) | 2002-03-13 | 2005-06-20 | Array Biopharma Inc | Derivados de bencimidazol n3 alquilados como inhibidores de mek. |
| PL1761528T3 (pl) | 2004-06-11 | 2008-05-30 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka |
| NZ563707A (en) | 2005-05-18 | 2011-01-28 | Array Biopharma Inc | Heterocyclic inhibitors of MEK and methods of use thereof |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| US20120115896A1 (en) * | 2008-12-03 | 2012-05-10 | Alberto Bardelli | Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| WO2012175520A1 (en) * | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| US20140348819A1 (en) * | 2011-06-24 | 2014-11-27 | Dana-Farber Cancer Institute, Inc. | Methods of Treating Cancer |
| US8815926B2 (en) * | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| EP2752191A1 (en) * | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| MX393610B (es) * | 2013-11-11 | 2025-03-24 | Amgen Inc | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres |
| WO2015084804A1 (en) * | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| WO2015095834A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using erk1/2 and bcl-2 family inhibitors |
| AU2014372166B2 (en) | 2013-12-23 | 2017-10-26 | Novartis Ag | Pharmaceutical combinations |
-
2016
- 2016-08-24 CA CA2992221A patent/CA2992221C/en active Active
- 2016-08-24 EP EP23177095.9A patent/EP4241850A3/en not_active Withdrawn
- 2016-08-24 RU RU2020142739A patent/RU2020142739A/ru unknown
- 2016-08-24 WO PCT/IB2016/055050 patent/WO2017037579A1/en not_active Ceased
- 2016-08-24 CN CN201680062336.8A patent/CN108348520A/zh active Pending
- 2016-08-24 ES ES16760803T patent/ES2962460T3/es active Active
- 2016-08-24 KR KR1020187005360A patent/KR20180041677A/ko not_active Ceased
- 2016-08-24 RU RU2018110770A patent/RU2740091C2/ru active
- 2016-08-24 CN CN202010783071.9A patent/CN111821306A/zh not_active Withdrawn
- 2016-08-24 JP JP2018510877A patent/JP2018528206A/ja active Pending
- 2016-08-24 AU AU2016314082A patent/AU2016314082B2/en not_active Ceased
- 2016-08-24 US US15/756,094 patent/US20190060309A1/en not_active Abandoned
- 2016-08-24 EP EP16760803.3A patent/EP3340989B1/en not_active Revoked
-
2018
- 2018-01-18 IL IL257015A patent/IL257015B/en unknown
-
2019
- 2019-07-09 AU AU2019204938A patent/AU2019204938B2/en not_active Ceased
-
2020
- 2020-09-09 IL IL277239A patent/IL277239B/en unknown
- 2020-11-17 JP JP2020190870A patent/JP2021042222A/ja active Pending
-
2021
- 2021-03-01 US US17/188,726 patent/US20210260059A1/en not_active Abandoned
-
2023
- 2023-01-13 US US18/154,717 patent/US20230398115A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3340989B1 (en) | 2023-08-16 |
| US20210260059A1 (en) | 2021-08-26 |
| CA2992221A1 (en) | 2017-03-09 |
| AU2019204938A1 (en) | 2019-07-25 |
| IL257015B (en) | 2022-02-01 |
| JP2018528206A (ja) | 2018-09-27 |
| ES2962460T3 (es) | 2024-03-19 |
| IL257015A (en) | 2018-03-29 |
| US20230398115A1 (en) | 2023-12-14 |
| EP4241850A3 (en) | 2023-11-08 |
| CN111821306A (zh) | 2020-10-27 |
| JP2021042222A (ja) | 2021-03-18 |
| EP3340989A1 (en) | 2018-07-04 |
| RU2018110770A3 (enExample) | 2020-01-15 |
| RU2740091C2 (ru) | 2021-01-11 |
| AU2016314082A1 (en) | 2018-02-08 |
| AU2019204938B2 (en) | 2020-07-16 |
| CN108348520A (zh) | 2018-07-31 |
| IL277239B (en) | 2022-04-01 |
| US20190060309A1 (en) | 2019-02-28 |
| AU2016314082B2 (en) | 2019-07-25 |
| EP4241850A2 (en) | 2023-09-13 |
| CA2992221C (en) | 2023-06-27 |
| WO2017037579A1 (en) | 2017-03-09 |
| KR20180041677A (ko) | 2018-04-24 |
| RU2020142739A3 (enExample) | 2021-05-20 |
| RU2018110770A (ru) | 2019-09-30 |
| IL277239A (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020142739A (ru) | Ингибиторы mdm2 и их комбинации | |
| JP2018528206A5 (enExample) | ||
| JP7274450B2 (ja) | 癌を処置するための医薬組合せ | |
| AU2009268469B2 (en) | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of Ras/Raf/Mek pathway | |
| JPWO2020130125A5 (enExample) | ||
| JP6532878B2 (ja) | 組合せ医薬 | |
| JP6508544B2 (ja) | 腫瘍を治療するための薬用組成物 | |
| JP6784668B2 (ja) | 相乗的オーリスタチン組合せ | |
| JP2018531983A (ja) | タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法 | |
| TR201800962T4 (en) | CDC7 KINAZI INHIBITORS AND THEIR USAGE | |
| JP2013544804A5 (enExample) | ||
| JP2019510832A5 (enExample) | ||
| JP2014505735A5 (enExample) | ||
| RU2015108755A (ru) | Комбинация ингибитора pik3 и ингибитора с-мет | |
| RU2018104702A (ru) | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ | |
| RU2016141569A (ru) | Комбинации | |
| JP2014518544A5 (enExample) | ||
| CA2793616A1 (en) | New combination therapy in treatment of oncological and fibrotic diseases | |
| JPWO2021060453A5 (enExample) | ||
| JP2015517523A5 (enExample) | ||
| Zhong et al. | Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways | |
| WO2016193955A1 (en) | Combinations of kinase inhibitors for treating colorectal cancer | |
| RU2015138576A (ru) | Комбинации соединения ингибитора мек с соединением ингибитором her3/egfr и способы применения | |
| TW202131917A (zh) | 併用醫藥 | |
| JP2018528949A5 (enExample) |